GLP-1 Medications for Joint Pain and Osteoarthritis: How Weight Loss Transforms Joint Health

The relationship between excess body weight and joint disease is both mechanical and metabolic. During walking, the knee experiences forces of 2–4 times body weight with each step, and stair climbing generates forces of 4–6 times body weight. For a person weighing 250 pounds, each step delivers 500–1,000 pounds of compressive force across the knee joint surfaces. Landmark research published in Arthritis & Rheumatism demonstrated that each pound of body weight corresponds to approximately 4 pounds of compressive force across the knee during walking. This means losing 10 pounds removes roughly 40 pounds of force per step — and the average person takes 6,000–10,000 steps per day. Over the course of a year, a 10-pound weight loss eliminates an estimated 87 million to 146 million pounds of cumulative knee loading. This mechanical unloading is the primary mechanism by which weight loss slows the progression of knee osteoarthritis and reduces pain. But the impact extends beyond biomechanics. Obesity promotes systemic inflammation through elevated levels of adipokines — pro-inflammatory cytokines produced by adipose tissue, including leptin, resistin, and adiponectin. These inflammatory mediators directly accelerate cartilage degradation by promoting the activity of matrix metalloproteinases (MMPs) — enzymes that break down the collagen and proteoglycan matrix of articular cartilage. This explains why obesity increases the risk of osteoarthritis not only in weight-bearing joints like the knees and hips but also in non-weight-bearing joints like the hands, suggesting a systemic inflammatory contribution independent of mechanical loading.

The STEP 9 trial, a dedicated study of semaglutide 2.4 mg in adults with knee osteoarthritis and obesity, was published in the New England Journal of Medicine in 2024. This randomized, double-blind trial enrolled 407 patients with symptomatic knee OA (Kellgren-Lawrence grade 2–3) and a BMI of 30 or higher. Over 68 weeks, the semaglutide group achieved mean weight loss of 13.7% compared to 3.2% with placebo. The primary endpoint — change in the WOMAC pain score — improved by 41.7 points in the semaglutide group versus 27.5 points with placebo (difference of 14.1 points, P < 0.001). Physical function improved by 42.6 points versus 26.7 points, and overall WOMAC scores improved by 41.5 versus 27.3 points. The six-minute walk test distance increased by 32 meters more in the semaglutide group, indicating meaningful improvement in functional capacity. C-reactive protein — a marker of systemic inflammation — decreased by 53% in the semaglutide group, compared to a 16% decrease with placebo. MRI analysis of a substudy cohort showed reduced synovial inflammation and trends toward slowed cartilage loss in the semaglutide group, though the study was not powered to detect structural changes as a primary outcome. Patient-reported outcomes showed that 56% of semaglutide-treated patients reported clinically meaningful pain improvement, defined as a 30% or greater reduction in WOMAC pain. Quality-of-life measures, including the SF-36 physical component score and the EQ-5D-5L, showed significant improvements.

Joint pain creates a devastating cycle of inactivity that accelerates both weight gain and joint deterioration. Patients with knee osteoarthritis walk an average of 35% fewer steps per day than age-matched controls without OA, according to accelerometer data from the Osteoarthritis Initiative. This inactivity reduces caloric expenditure by 200–400 calories per day, promotes further weight gain, increases insulin resistance, accelerates muscle atrophy (particularly of the quadriceps, which is the primary dynamic stabilizer of the knee), and worsens cardiovascular fitness. The resulting deconditioning creates additional barriers to exercise-based weight loss, trapping patients in a cycle where joint pain prevents the physical activity needed to lose the weight that is causing the joint pain. GLP-1 medications break this cycle by producing significant weight loss without requiring exercise as the primary driver. As weight decreases and joint loading diminishes, pain decreases sufficiently to allow progressive physical activity. In the STEP 9 trial, patients on semaglutide reported significantly improved ability to participate in exercise and daily activities. A secondary analysis showed that physical activity levels (measured by accelerometer) increased by 18% in the semaglutide group, compared to a 3% increase with placebo. This exercise enablement creates a positive feedback loop: weight loss reduces pain, reduced pain allows more activity, more activity promotes further weight loss and joint health, and the resulting muscle strengthening provides better joint stability. Physical therapists increasingly recognize GLP-1 therapy as a catalyst that makes their rehabilitation programs more feasible and effective for obese patients with osteoarthritis.

While knee osteoarthritis receives the most research attention, obesity-related joint pain extends to the hips, lumbar spine, ankles, and feet. Lumbar spine loading increases proportionally with abdominal adiposity, and a BMI above 30 is associated with a 2.5-fold increased risk of symptomatic lumbar disc degeneration and a 2-fold increased risk of lumbar spinal stenosis. The mechanical effect of excess abdominal weight shifts the center of gravity anteriorly, increasing lumbar lordosis and compressive loading on the posterior spinal elements, accelerating facet joint arthropathy and disc degeneration. Hip osteoarthritis shares the same biomechanical principles as knee OA, with joint forces during walking exceeding 3–5 times body weight. A prospective study in Annals of the Rheumatic Diseases found that each 5-unit increase in BMI raised the risk of hip replacement by 36%. Obesity-related foot and ankle problems, including plantar fasciitis, posterior tibial tendon dysfunction, and ankle osteoarthritis, are common but under-studied contributors to disability and inactivity. Weight loss of 10–15% has been shown to significantly reduce pain and improve function across all weight-bearing joints. While the STEP 9 trial focused on knee OA, observational data from GLP-1-treated patients show improvements in back pain, hip pain, and foot pain that parallel knee pain improvements. A 2023 survey of 500 patients taking semaglutide for weight loss found that 72% reported improvement in at least one joint pain complaint, with knee pain (68%), back pain (61%), and hip pain (48%) being the most commonly improved symptoms.

Joint replacement surgery — total knee arthroplasty (TKA) and total hip arthroplasty (THA) — is the definitive treatment for end-stage osteoarthritis, with over 1.2 million procedures performed annually in the United States. However, obesity significantly increases surgical risk: patients with a BMI above 40 have a 2–3 fold higher rate of surgical site infection, a 1.5-fold higher rate of prosthetic joint infection, a 2-fold higher rate of wound complications, and higher rates of medical complications including deep vein thrombosis and pulmonary embolism. Many orthopedic surgeons require patients to achieve a BMI below 35–40 before proceeding with elective joint replacement, creating a frustrating barrier for patients whose obesity-related joint pain limits the exercise they need to lose weight. GLP-1 medications offer a practical solution to preoperative weight optimization. A 2024 retrospective cohort study at the Cleveland Clinic examined 180 patients who used GLP-1 agonists for weight loss before elective TKA. The group achieved a mean weight loss of 14.2% over 6–9 months, with 78% meeting their surgeon's BMI threshold for surgery. Postoperative complication rates were comparable to non-obese patients, and 1-year functional outcomes (measured by Knee Society Score) were significantly better than historical obese controls who underwent TKA without preoperative weight loss. For patients who achieve sufficient pain relief with GLP-1-mediated weight loss, joint replacement may be delayed or avoided entirely. At Weight Method, semaglutide ($297/month) and tirzepatide ($349/month) can serve as both a direct treatment for joint pain and a preoperative optimization tool.